SOURCE: CLX Investment Company, Inc.

August 03, 2006 09:55 ET

CLX Investment Company Issues August 2006 Newsletter

TEMECULA, CA -- (MARKET WIRE) -- August 3, 2006 --CLX Investment Company, Inc. (OTCBB: CLXN), a diversified investment fund with holdings in e-learning, global advertising and diagnostic testing markets, today issued the August 2006 edition of its investor newsletter, which is almost entirely dedicated to the continued growth of portfolio company Zonda, Incorporated and its expansion into new global markets.

A full-color PDF version of the August newsletter can be viewed and downloaded at www.clxinvestments.com/newsletters.asp.

"With Zonda making such significant strides to become a worldwide supplier of its HandiLab line of medical diagnostic testing products, we felt that it was important to highlight this progress for our shareholders," said Robert McCoy, chief executive officer of CLX Investment Company. "We expect Zonda and our other portfolio companies to be no less active this month, and CLX will maintain the flow of information to its shareholders as events dictate."

The newsletter includes an article on Zonda's recent successful appearance at the American Association for Clinical Chemistry's 2006 Annual Meeting and Exposition held in Chicago. It also discusses the initiation of coverage on CLX by The MacReport.net, an information and media firm that provides a forum for companies to communicate corporate audio and video news content to the business, financial and investing community through its website.

To sign up to receive information by email directly from CLX Investment Company when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit http://www.clxinvestments.com/email.asp.

About Zonda, Inc.

Zonda, Inc. (www.zondaincusa.com), in which CLX holds a 31% equity interest, specializes in diagnostic tests that serve the medical, bacterial food safety, cosmetic, beverage, pharmaceutical, veterinary, and environmental sanitation testing markets. Zonda's product line includes innovative, rapid, self-contained diagnostic devices for the detection of chlamydia, gonorrhea, yeast (Candida albicans) and Group A Strep, tests that detect bacterial and other potential harmful micro-organisms on surfaces, and confirmation tests for a wide variety of bacteria. The HandiLab-C test for chlamydia carries a CE mark for both professional point-of-care and over-the-counter use. The gonorrhea, yeast and Group A Strep tests carry CE marks for professional point-of-care use, and Zonda is seeking similar approvals for over-the-counter sales of these products. Each of the Zonda infectious disease tests are marketed as superior to their competition due to their comparable accuracy (compared directly to PCR or DNA testing), ease of use, compact design, long shelf life, rapid results, and cost effectiveness.

About CLX Investment Company

CLX Investment Company (www.clxinvestments.com) holds a 31% equity interest in Zonda, Inc. (www.zondaincusa.com). Also in the CLX investment portfolio is a 49% interest in eStrategy Solutions, Inc. (www.estrategysolutions.com), a Texas-based e-learning provider that has developed online training solutions for government entities and other professional organizations. CLX has invested, and holds a common stock position, in ActionView International, Inc. (www.actionviewinternational.com), a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards.

CLX has elected to be regulated as a Business Development Company pursuant to Section 54 of the Investment Company Act of 1940, and is pursuing a business plan wherein the Company seeks to make investment in developing companies with the goal of providing return for its shareholders.

All statements included in this release, including statements regarding potential future plans and objectives of CLX Investments are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Investments' control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.

Contact Information

  • Contact:
    Gemini Financial Communications
    A. Beyer
    951-587-8072
    Email Contact